115 related articles for article (PubMed ID: 3422589)
1. A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action.
Mills GB; May C; McGill M; Roifman CM; Mellors A
Cancer Res; 1988 Mar; 48(5):1066-71. PubMed ID: 3422589
[TBL] [Abstract][Full Text] [Related]
2. Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells.
Mills GB; May C; Hill M; Campbell S; Shaw P; Marks A
J Clin Invest; 1990 Sep; 86(3):851-5. PubMed ID: 2394835
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
4. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients.
Xu Y; Gaudette DC; Boynton JD; Frankel A; Fang XJ; Sharma A; Hurteau J; Casey G; Goodbody A; Mellors A
Clin Cancer Res; 1995 Oct; 1(10):1223-32. PubMed ID: 9815916
[TBL] [Abstract][Full Text] [Related]
5. The role of peptide growth factors in epithelial ovarian cancer.
Berchuck A; Olt GJ; Everitt L; Soisson AP; Bast RC; Boyer CM
Obstet Gynecol; 1990 Feb; 75(2):255-62. PubMed ID: 2300354
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression.
Wu S; Boyer CM; Whitaker RS; Berchuck A; Wiener JR; Weinberg JB; Bast RC
Cancer Res; 1993 Apr; 53(8):1939-44. PubMed ID: 8385577
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of transforming growth factor beta receptors by androgen in ovarian cancer cells.
Evangelou A; Jindal SK; Brown TJ; Letarte M
Cancer Res; 2000 Feb; 60(4):929-35. PubMed ID: 10706107
[TBL] [Abstract][Full Text] [Related]
8. A putative growth factor in extract from uterine cancers.
Matsunami K; Imai A; Tamaya T
Res Commun Chem Pathol Pharmacol; 1989 Dec; 66(3):477-80. PubMed ID: 2609022
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
[TBL] [Abstract][Full Text] [Related]
10. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
11. The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium.
Dabrow MB; Francesco MR; McBrearty FX; Caradonna S
Gynecol Oncol; 1998 Oct; 71(1):29-37. PubMed ID: 9784315
[TBL] [Abstract][Full Text] [Related]
12. Peptide and lipid growth factors decrease cis-diamminedichloroplatinum-induced cell death in human ovarian cancer cells.
Frankel A; Mills GB
Clin Cancer Res; 1996 Aug; 2(8):1307-13. PubMed ID: 9816301
[TBL] [Abstract][Full Text] [Related]
13. The granulin-epithelin precursor/PC-cell-derived growth factor is a growth factor for epithelial ovarian cancer.
Jones MB; Michener CM; Blanchette JO; Kuznetsov VA; Raffeld M; Serrero G; Emmert-Buck MR; Petricoin EF; Krizman DB; Liotta LA; Kohn EC
Clin Cancer Res; 2003 Jan; 9(1):44-51. PubMed ID: 12538450
[TBL] [Abstract][Full Text] [Related]
14. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.
Pedersen N; Schmitt M; Rønne E; Nicoletti MI; Høyer-Hansen G; Conese M; Giavazzi R; Dano K; Kuhn W; Jänicke F
J Clin Invest; 1993 Nov; 92(5):2160-7. PubMed ID: 8227331
[TBL] [Abstract][Full Text] [Related]
15. Loss of coordinated androgen regulation in nonmalignant ovarian epithelial cells with BRCA1/2 mutations and ovarian cancer cells.
Evangelou A; Letarte M; Jurisica I; Sultan M; Murphy KJ; Rosen B; Brown TJ
Cancer Res; 2003 May; 63(10):2416-24. PubMed ID: 12750261
[TBL] [Abstract][Full Text] [Related]
16. Involvement of transforming growth factor beta1 in autocrine enhancement of gelatinase B secretion by murine metastatic colon carcinoma cells.
Shimizu S; Nishikawa Y; Kuroda K; Takagi S; Kozaki K; Hyuga S; Saga S; Matsuyama M
Cancer Res; 1996 Jul; 56(14):3366-70. PubMed ID: 8764135
[TBL] [Abstract][Full Text] [Related]
17. [Growth regulation of human ovarian cancer cells by growth factors in vitro].
Chen X; Gao Y; Sun Y
Zhonghua Fu Chan Ke Za Zhi; 1996 Dec; 31(12):740-3. PubMed ID: 9387517
[TBL] [Abstract][Full Text] [Related]
18. Regulation of ovarian UT-OC-2 carcinoma cells by cytokines: effects on cell proliferation, activation of transcription factors and apoptosis.
Seppänen M; Lin L; Saarinen R; Punnonen R; Vihko KK
Acta Obstet Gynecol Scand; 2008; 87(9):902-9. PubMed ID: 18720042
[TBL] [Abstract][Full Text] [Related]
19. Defective antitumor function of monocyte-derived macrophages from epithelial ovarian cancer patients.
Gordon IO; Freedman RS
Clin Cancer Res; 2006 Mar; 12(5):1515-24. PubMed ID: 16533776
[TBL] [Abstract][Full Text] [Related]
20. Partial purification and characterization of a lymphocyte-inhibitory factor(s) in ascitic fluids from ovarian cancer patients.
Hess AD; Gall SA; Dawson JR
Cancer Res; 1980 Jun; 40(6):1842-51. PubMed ID: 6966184
[No Abstract] [Full Text] [Related]
[Next] [New Search]
